


Please amend the claims as follows:

E1
Claim 1. (Three Times Amended) A method for treating or alleviating a disease or disorder selected from the group consisting of Addison's disease, alopecia areata, Ankylosing spondylitis, haemolytic anemia (anemia haemolytica), pernicious anemia (anemia perniciosa), aphthae, aphthous stomatitis, osteoarthritis, rheumatoid arthritis, aspermiogenese, asthma bronchiale, auto-immune asthma, auto immune hemolysis, Bechet's disease, Boeck's disease, inflammatory bowel disease, Burkitt's lymphoma, Chron's disease, chorioiditis, colitis ulcerosa, Coeliac disease, cryoglobulinemia, dermatitis herpetiformis, dermatomyositis, insulin-dependent type I diabetes, juvenile diabetes, idiopathic diabetes insipidus, insulin-dependent diabetes mellisis, auto-immune demyelinating diseases, Dupuytren's contracture, encephalomyelitis, encephalomyelitis allergica, endophthalmia phacoanaphylactica, enteritis allergica, autoimmune enteropathy syndrome, erythema nodosum leprosum, idiopathic facial paralysis, chronic fatigue syndrome, febris rheumatica, glomerulo nephritis, Goodpasture's syndrome, Graves' disease, Hamman-Rich's disease, Hashimoto's disease, Hashimoto's thyroiditis, sudden hearing loss, ensoneural hearing loss, hepatitis chronica, Hodgkin's disease, haemoglobinuria paroxysmatica, hypogonadism,

ileitis regionalis, iritis, leucopenia, leucemia, lupus erythematosus disseminatus, systemic lupus erythematosus, cutaneous lupus erythematosus, lymphogranuloma malignum, mononucleosis infectiosa, myasthenia gravis, transverse myelitis, primary idiopathic myxedema, nephrosis, ophthalmia sympathica, orchitis granulomatosa, pancreatitis, pemphigus, pemphigus vulgaris, polyarteritis nodosa, polyarthritidis chronica primaria, polymyositis, polyradiculitis acuta, psoriasis, purpura, pyoderma gangrenosum, Quervain's thyroiditis, Reiter's syndrome, sarcoidosis, ataxic sclerosis, progressive systemic sclerosis, scleritis, multiple sclerosis, sclerosis disseminata, acquired splenic atrophy, infertility due to antispermatozoan antibodies, thrombocytopenia, idiopathic thrombocytopenia purpura, thymoma, acute anterior uveitis, and vitiligo,

said method comprising administering a therapeutically effective amount of a chemical compound having selective IK_{Ca} modulatory activity to said mammal, wherein the chemical compound is a triaryl methane derivative represented by Formula I



and a pharmaceutically acceptable salt or an oxide or a hydrate thereof, wherein

n is 0, 1, 2, 3, 4, 5 or 6;

X is absent, or represent a group of the formula $-(CH_2)_n-$, of the formula $-(CH_2)_n-Z-$ (in either direction), of the formula $-(CH_2)_n-CH=N-$ (in either direction), the formula $-(CH_2)_n-Z-(CH_2)_m-$, or of the formula $-(CH_2)_n-CH=N-(CH_2)_m$ (in either direction) or a group of the formula $-R'''C(O)N-$;

in which formulas

n and m, independently of each another, represent 0, 1, 2, 3 or 4; and

Z represents O, S, or NR''' , wherein R''' represents hydrogen or alkyl;

Y represents a carbon atom (C), a nitrogen atom (N), or a phosphor atom (P), a silicium atom (Si), or a germanium atom (Ge);

Ar^1 , Ar^2 and Ar^3 , independently of each another, represents a mono- or polycyclic aryl group selected from the group consisting of phenyl, biphenyl, naphthyl, and cyclopenta-2,4-diene-1-ylidene, or a mono- or poly-heterocyclic group, wherein the mono- or poly-heterocyclic group is a 5- and 6 membered heterocyclic monocyclic group selected from the group consisting of furanyl, imidazolyl, isoimidazolyl, 2-isoimidazolyl, isothiazolyl,


isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl, piperidyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, and butyrolactonyl, which mono- or polycyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, cyano, -OR'', -SR'', -R'OR'', -R'SR'', -C(O)R'', -C(S)R'', -C(O)OR'', -C(S)OR'', -C(O)SR'', -C(S)SR'', -C(O)NR'(OR''), -C(S)NR'(OR''), -C(O)NR'(SR''), -C(S)NR'(SR''), -CH(CN)₂, -C(O)NR''₂, -C(S)NR''₂, -CH[C(O)R'']₂, -CH[C(S)R'']₂, -CH[C(O)OR'']₂, -CH[C(S)OR'']₂, -CH[C(O)SR'']₂, -CH[C(S)SR'']₂, -CH₂OR'', and -CH₂SR'';

R represents hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro or cyano, or a group of the formula -OR', -SR', -R''OR', -R''SR', -C(O)R', -C(S)R', -C(O)OR', -C(S)OR', -C(O)SR', -C(S)SR', -C(O)NR''(OR'), -C(S)NR''(OR'), -C(O)NR''(SR'), -C(S)NR''(SR'), -CH(CN)₂, -C(O)NR'₂, -C(S)NR'₂, -CH[C(O)R']₂, -CH[C(S)R']₂, -CH[C(O)OR']₂, -CH[C(S)OR']₂, -CH[C(O)SR']₂, -CH[C(S)SR']₂, -CH₂OR', or -CH₂SR'; or a mono- or polycyclic aryl group selected from the group consisting of phenyl, biphenyl, naphthyl, and cyclopenta-2,4-diene-1-ylidene, or a mono-

E₁ or poly-heterocyclic group, wherein the mono- or poly-heterocyclic group is a 5- and 6 membered heterocyclic monocyclic group selected from the group consisting of furanyl, imidazolyl, isoimidazolyl, 2-isoimidazolyl, isothiazolyl, isoxazolyl, 1,2,3 oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl, piperidyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, and butyrolactonyl, which mono- or polycyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, cyano, -OR', and -SR'; and

R' and R", independently of each another, represents hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, or alkoxy.

E₂ Claim 4. (Three Times Amended) The method according to claim 1, wherein the chemical compound is a triaryl methane derivative represented by Formula II



and a pharmaceutically acceptable salt or an oxide or a hydrate thereof, wherein,

n is 0, 1, 2, 3, 4, 5 or 6;

Ar^1 represents a mono- or polycyclic aryl group selected from the group consisting of phenyl, biphenyl, naphthyl, and cyclopenta-2,4 diene-1-ylidene, or a mono- or poly-heterocyclic group, wherein said mono- or poly-heterocyclic group is a 5- and 6 membered heterocyclic monocyclic group selected from the group consisting of furanyl, imidazolyl, isoimidazolyl, 2-isoimidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl, piperidyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, and butyrolactonyl, and which mono- or polycyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, cyano, $-OR''$, $-SR''$,

-R'OR", -R'SR", -C(O)R", -C(S)R", -C(O)OR", -C(S)OR", -C(O)SR",
 -C(S)SR", -C(O)NR'(OR"), -C(S)NR'(OR"), -C(O)NR'(SR"),
 -C(S)NR'(SR"), -CH(CN)₂, -C(O)NR"₂, -C(S)NR"₂, -CH[C(O)R"]₂,
 -CH[C(S)R"]₂, -CH[C(O)OR"]₂, -CH[C(S)OR"]₂, -CH[C(O)SR"]₂,
 -CH[C(S)SR"]₂, -CH₂OR", and -CH₂SR";


E₂ R represents hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro or cyano, or a group of the formula -OR', -SR', -R"OR', -R"SR', -C(O)R', -C(S)R', -C(O)OR', -C(S)OR', -C(O)SR', -C(S)SR', -C(O)NR"(OR'), -C(S)NR"(OR'), -C(O)NR"(SR'), -C(S)NR"(SR'), -CH(CN)₂, -C(O)NR'₂, -C(S)NR'₂, -CH[C(O)R']₂, -CH[C(S)R']₂, -CH[C(O)OR']₂, -CH[C(S)OR']₂, -CH[C(O)SR']₂, -CH[C(S)SR']₂, -CH₂OR', or -CH₂SR'; or a mono- or polycyclic aryl group, or a mono- or poly-heterocyclic group, which mono- or polycyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, cyano, -OR', and -SR';

which triaryl methane derivative may further be substituted one or more times with a substituent X selected from the group consisting of hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, cyano, -OR", -SR", -R'OR", -R'SR", -C(O)R", -C(S)R", -C(O)OR", -C(S)OR", -C(O)SR",

-C(S)SR", -C(O)NR'(OR"), -C(S)NR'(OR"), -C(O)NR'(SR"),
 -C(S)NR'(SR"), -CH(CN)₂, -C(O)NR"₂, -C(S)NR"₂, -CH[C(O)R"]₂,
 E2 -CH[C(S)R"]₂, -CH[C(O)OR"]₂, -CH[C(S)OR"]₂, -CH[C(O)SR"]₂,
 -CH[C(S)SR"]₂, -CH₂OR", and -CH₂SR"; and

R' and R", independently of each another, represents hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, or alkoxy.

Claim 6. (Three Times Amended) The method according to claim 1, wherein the triaryl methane derivative is represented by Formula III



and a pharmaceutically acceptable salt or an oxide or a hydrate thereof, wherein,

n is 0, 1, 2, 3, 4, 5, or 6;

R represents hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro or cyano, or a group of


the formula $-\text{OR}'$, $-\text{SR}'$, $-\text{R}''\text{OR}'$, $-\text{R}''\text{SR}'$, $-\text{C}(\text{O})\text{R}'$, $-\text{C}(\text{S})\text{R}'$, $-\text{C}(\text{O})\text{OR}'$, $-\text{C}(\text{S})\text{OR}'$, $-\text{C}(\text{O})\text{SR}'$, $-\text{C}(\text{S})\text{SR}'$, $-\text{C}(\text{O})\text{NR}''(\text{OR}')$, $-\text{C}(\text{S})\text{NR}''(\text{OR}')$, $-\text{C}(\text{O})\text{NR}''(\text{SR}')$, $-\text{C}(\text{S})\text{NR}''(\text{SR}')$, $-\text{CH}(\text{CN})_2$, $-\text{C}(\text{O})\text{NR}'_2$, $-\text{C}(\text{S})\text{NR}'_2$, $-\text{CH}[\text{C}(\text{O})\text{R}']_2$, $-\text{CH}[\text{C}(\text{S})\text{R}']_2$, $-\text{CH}[\text{C}(\text{O})\text{OR}']_2$, $-\text{CH}[\text{C}(\text{S})\text{OR}']_2$, $-\text{CH}[\text{C}(\text{O})\text{SR}']_2$, $-\text{CH}[\text{C}(\text{S})\text{SR}']_2$, $-\text{CH}_2\text{OR}'$, or $-\text{CH}_2\text{SR}'$; or a mono- or polycyclic aryl group selected from the group consisting of phenyl, biphenyl, naphthyl, and cyclopenta-2,4-diene-1-ylidene, or a mono- or poly-heterocyclic group, wherein said mono- or poly-heterocyclic group is a 5- and 6-membered heterocyclic monocyclic group selected from the group consisting of furanyl, imidazolyl, isoimidazolyl, 2-isoimidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl, piperidyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, and butyrolactonyl, and which mono- or polycyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, cyano, $-\text{OR}'$, and $-\text{SR}'$;

R^1 , R^2 , R^3 and R^4 , independently of each another, represents hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro or cyano, or a group of the formula $-\text{OR}''$, $-\text{SR}''$, $-\text{R}'\text{OR}''$, $-\text{R}'\text{SR}''$, $-\text{C}(\text{O})\text{R}''$, $-\text{C}(\text{S})\text{R}''$, $-\text{C}(\text{O})\text{OR}''$,

E3 -C(S)OR", -C(O)SR", -C(S)SR", -C(O)NR'(OR"), -C(S)NR'(OR"),
 -C(O)NR'(SR"), -C(S)NR'(SR"), -CH(CN)₂, -C(O)NR"₂, -C(S)NR"₂,
 -CH[C(O)R"]₂, -CH[C(S)R"]₂, -CH[C(O)OR"]₂, -CH[C(S)OR"]₂,
 -CH[C(O)SR"]₂, -CH[C(S)SR"]₂, -CH₂OR", or -CH₂SR"; and

R' and R", independently of each other, represents hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, or alkoxy.

Claim 8. (Three Times Amended) The method according to claim 1, wherein the triaryl methane derivative is represented by Formula IV



and a pharmaceutically acceptable salt or an oxide or a hydrate thereof, wherein,

n is 0, 1, 2, 3, 4, 5, or 6;

R represents hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro or cyano, or a group of


the formula $-OR'$, $-SR'$, $-R''OR'$, $-R''SR'$, $-C(O)R'$, $-C(S)R'$, $-C(O)OR'$, $-C(S)OR'$, $-C(O)SR'$, $-C(S)SR'$, $-C(O)NR''(OR')$, $-C(S)NR''(OR')$, $-C(O)NR''(SR')$, $-C(S)NR''(SR')$, $-CH(CN)_2$, $-C(O)NR'_2$, $-C(S)NR'_2$, $-CH[C(O)R']_2$, $-CH[C(S)R']_2$, $-CH[C(O)OR']_2$, $-CH[C(S)OR']_2$, $-CH[C(O)SR']_2$, $-CH[C(S)SR']_2$, $-CH_2OR'$, or $-CH_2SR'$; or a mono- or polycyclic aryl group selected from the group consisting of phenyl, biphenyl, naphthyl, and cyclopenta-2,4-diene-1-ylidene, or a mono- or poly-heterocyclic group, wherein said mono- or poly-heterocyclic group is a 5- and 6 membered heterocyclic monocyclic group selected from the group consisting of furanyl, imidazolyl, isoimidazolyl, 2-isoimidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl, piperidyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, and butyrolactonyl, and which mono- or polycyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, cyano, $-OR'$, and $-SR'$;

R^1 , R^2 and R^3 , independently of each another, represents hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl,

alkynyl, amino, nitro or cyano, or a group of the formula -OR",
 -SR", -R'OR", -R'SR", -C(O)R", -C(S)R", -C(O)OR", -C(S)OR",
 -C(O)SR", -C(S)SR", -C(O)NR'(OR"), -C(S)NR'(OR"),
 -C(O)NR'(SR"), -C(S)NR'(SR"), -CH(CN)₂, -C(O)NR"₂, -C(S)NR"₂,
 -CH[C(O)R"]₂, -CH[C(S)R"]₂, -CH[C(O)OR"]₂, -CH[C(S)OR"]₂,
 -CH[C(O)SR"]₂, -CH[C(S)SR"]₂, -CH₂OR", or -CH₂SR"; and

R' and R", independently of each another, represents hydrogen,
 alkyl, cycloalkyl, alkenyl, alkynyl, or alkoxy.

Claim 10. (Three Times Amended) The method according to
 claim 1, wherein the triaryl methane derivative is represented by
 Formula V



and a pharmaceutically acceptable salt or an oxide or a hydrate
 thereof, wherein,

n is 0, 1, 2, 3, 4, 5, or 6;

Ar¹ represents a mono- or polycyclic aryl group selected from
 the group consisting phenyl, biphenyl, naphthyl, and

cyclopenta-2,4-diene-1-ylidene, or a mono- or poly-heterocyclic group, wherein said mono- or poly-heterocyclic group is a 5- and 6-membered heterocyclic monocyclic group selected from the group consisting of furanyl, imidazolyl, isoimidazolyl, 2-isoimidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl, piperidyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, and butyrolactonyl, and which mono- or polycyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, cyano, -OR", -SR", -R'OR", -R'SR", -C(O)R", -C(S)R", -C(O)OR", -C(S)OR", -C(O)SR", -C(S)SR", -C(O)NR'(OR"), -C(S)NR'(OR"), -C(O)NR'(SR"), -C(S)NR'(SR"), -CH(CN)₂, -C(O)NR"₂, -C(S)NR"₂, -CH[C(O)R"]₂, -CH[C(S)R"]₂, -CH[C(O)OR"]₂, -CH[C(S)OR"]₂, -CH[C(O)SR"]₂, -CH[C(S)SR"]₂, -CH₂OR", and -CH₂SR";

R represents hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro or cyano, or a group of the formula -OR', -SR', -R"OR', -R"SR', -C(O)R', -C(S)R', -C(O)OR', -C(S)OR', -C(O)SR', -C(S)SR', -C(O)NR"(OR'), -C(S)NR"(OR'), -C(O)NR"(SR'), -C(S)NR"(SR'), -CH(CN)₂, -C(O)NR'₂, -C(S)NR'₂,

-CH[C(O)R']₂, -CH[C(S)R']₂, -CH[C(O)OR']₂, -CH[C(S)OR']₂,
 -CH[C(O)SR']₂, -CH[C(S)SR']₂, -CH₂OR', or -CH₂SR'; or a mono- or
 polycyclic aryl group selected from the group consisting phenyl,
 biphenyl, naphthyl, and cyclopenta-2,4-diene-1-ylidene, or a mono-
 or poly-heterocyclic group, wherein said mono- or poly-heterocyclic
 group is a 5- and 6-membered heterocyclic monocyclic group selected
 from the group consisting of furanyl, imidazolyl, isoimidazolyl,
 2-isoimidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl,
 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl,
 piperidyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl,
 pyrrolidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, and
 butyrolactonyl, and which mono- or polycyclic groups may optionally
 be substituted one or more times with substituents selected from
 the group consisting of hydrogen, halogen, trihalogenmethyl, alkyl,
 cycloalkyl, alkenyl, alkynyl, amino, nitro, cyano, -OR', and -SR';


R¹ and R², independently of each another, represents hydrogen,
 halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl,
 amino, nitro or cyano, or a group of the formula -OR'', -SR'',
 -R'OR'', -R'SR'', -C(O)R'', -C(S)R'', -C(O)OR'', -C(S)OR'', -C(O)SR'',
 -C(S)SR'', -C(O)NR'(OR''), -C(S)NR'(OR''), -C(O)NR'(SR''),
 -C(S)NR'(SR''), -CH(CN)₂, -C(O)NR''₂, -C(S)NR''₂, -CH[C(O)R'']₂,

-CH[C(S)R"]₂, -CH[C(O)OR"]₂, -CH[C(S)OR"]₂, -CH[C(O)SR"]₂,

ES -CH[C(S)SR"]₂, -CH₂OR", or -CH₂SR"; and

R' and R", independently of each another, represents hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, or alkoxy.

Claim 12. (Three Times Amended) The method according to claim 1, wherein the triaryl methane derivative is represented by Formula VI



and a pharmaceutically acceptable salt or an oxide or a hydrate thereof, wherein,

n is 0, 1, 2, 3, 4, 5, or 6;

R represents hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro or cyano, or a group of the formula -OR', -SR', -R"OR', -R"SR', -C(O)R', -C(S)R', -C(O)OR', -C(S)OR', -C(O)SR', -C(S)SR', -C(O)NR" (OR'), -C(S)NR" (OR'),


-C(O)NR''(SR'), -C(S)NR''(SR'), -CH(CN)₂, -C(O)NR'₂, -C(S)NR'₂,
 -CH[C(O)R']₂, -CH[C(S)R']₂, -CH[C(O)OR']₂, -CH[C(S)OR']₂,
 -CH[C(O)SR']₂, -CH[C(S)SR']₂, -CH₂OR', or -CH₂SR'; or a mono- or
 polycyclic aryl group selected from the group consisting of phenyl,
 biphenyl, naphthyl, and cyclopenta-2,4-diene-1-ylidene, or a mono-
 or poly-heterocyclic group, wherein said mono- or poly-heterocyclic
 group is a 5- and 6-membered heterocyclic monocyclic group selected
 from the group consisting of furanyl, imidazolyl, isoimidazolyl,
 2-isoimidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl,
 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl,
 piperidyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl,
 pyrrolidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, and
 butyrolactonyl, and which mono- or polycyclic groups may optionally
 be substituted one or more times with substituents selected from
 the group consisting of hydrogen, halogen, trihalogenmethyl,
 alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, cyano, -OR', and
 -SR';

R¹, R², R³ and R⁴, independently of each another, represents
 hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl,
 alkynyl, amino, nitro or cyano, or a group of the formula -OR'',
 -SR'', -R'OR'', -R'SR'', -C(O)R'', -C(S)R'', -C(O)OR'', -C(S)OR'',
 -C(O)SR'', -C(S)SR'', -C(O)NR'(OR''), -C(S)NR'(OR''), -C(O)NR'(SR''),

E6
 $-C(S)NR'(SR'')$, $-CH(CN)_2$, $-C(O)NR''_2$, $-C(S)NR''_2$, $-CH[C(O)R'']_2$,
 $-CH[C(S)R'']_2$, $-CH[C(O)OR'']_2$, $-CH[C(S)OR'']_2$, $-CH[C(O)SR'']_2$,
 $-CH[C(S)SR'']_2$, $-CH_2OR''$, or $-CH_2SR''$; and

R' and R'', independently of each another, represents hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, or alkoxy.

Claim 14. (Three Times Amended) The method according to claim 1, wherein the triaryl methane derivative is represented by Formula VII



and a pharmaceutically acceptable salt or an oxide or a hydrate thereof, wherein,

n is 0, 1, 2, 3, 4, 5, or 6;

R represents hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro or cyano, or a group of the formula $-OR'$, $-SR'$, $-R''OR'$, $-R''SR'$, $-C(O)R'$, $-C(S)R'$, $-C(O)OR'$,


-C(S)OR', -C(O)SR', -C(S)SR', -C(O)NR"(OR'), -C(S)NR"(OR'),
 -C(O)NR"(SR'), -C(S)NR"(SR'), -CH(CN)₂, -C(O)NR'₂, -C(S)NR'₂,
 -CH[C(O)R']₂, -CH[C(S)R']₂, -CH[C(O)OR']₂, -CH[C(S)OR']₂,
 -CH[C(O)SR']₂, -CH[C(S)SR']₂, -CH₂OR', or -CH₂SR'; or a mono- or
 polycyclic aryl group selected from the group consisting of phenyl,
 biphenyl, naphthyl, and cyclopenta-2,4-diene-1-ylidene, or a mono-
 or poly-heterocyclic group, wherein said mono- or poly-heterocyclic
 group is a 5- and 6-membered heterocyclic monocyclic group selected
 from the group consisting of furanyl, imidazolyl, isoimidazolyl,
 2-isoimidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl,
 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl,
 piperidyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl,
 pyrrolidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, and
 butyrolactonyl, and which mono- or polycyclic groups may optionally
 be substituted one or more times with substituents selected from
 the group consisting of hydrogen, halogen, trihalogenmethyl, alkyl,
 cycloalkyl, alkenyl, alkynyl, amino, nitro, cyano, -OR', and -SR';

R¹, R² and R³, independently of each another, represents
 hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl,
 alkynyl, amino, nitro or cyano, or a group of the formula -OR",
 -SR", -R'OR", -R'SR", -C(O)R", -C(S)R", -C(O)OR", -C(S)OR",
 -C(O)SR", -C(S)SR", -C(O)NR'(OR"), -C(S)NR'(OR"),

E7 $-C(O)NR'(SR'')$, $-C(S)NR'(SR'')$, $-CH(CN)_2$, $-C(O)NR''_2$, $-C(S)NR''_2$,
 $-CH[C(O)R'']_2$, $-CH[C(S)R'']_2$, $-CH[C(O)OR'']_2$, $-CH[C(S)OR'']_2$,
 $-CH[C(O)SR'']_2$, $-CH[C(S)SR'']_2$, $-CH_2OR''$, or $-CH_2SR''$; and

R' and R'', independently of each another, represents hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, or alkoxy.

Claim 16. (Three Times Amended) The method according to claim 1, wherein the triaryl methane derivative is represented by Formula VIII



and a pharmaceutically acceptable salt or an oxide or a hydrate thereof, wherein,

n is 0, 1, 2, 3, 4, 5, or 6;

Ar¹ represents a mono- or polycyclic aryl group selected from the group consisting of phenyl, biphenyl, naphthyl, and cyclopenta-2,4-diene-1-ylidene, or a mono- or poly-heterocyclic group, wherein said mono- or poly-heterocyclic group is a 5- and 6 membered heterocyclic monocyclic group selected from the group

consisting of furanyl, imidazolyl, isoimidazolyl, 2-isoimidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl, piperidyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, and butyrolactonyl, and which mono- or polycyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, cyano, -OR", -SR", -R'OR", -R'SR", -C(O)R", -C(S)R", -C(O)OR", -C(S)OR", -C(O)SR", -C(S)SR", -C(O)NR'(OR"), -C(S)NR'(OR"), -C(O)NR'(SR"), -C(S)NR'(SR"), -CH(CN)₂, -C(O)NR"₂, -C(S)NR"₂, -CH[C(O)R"]₂, -CH[C(S)R"]₂, -CH[C(O)OR"]₂, -CH[C(S)OR"]₂, -CH[C(O)SR"]₂, -CH[C(S)SR"]₂, -CH₂OR", and -CH₂SR";

R represents hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro or cyano, or a group of the formula -OR', -SR', -R"OR', -R"SR', -C(O)R', -C(S)R', -C(O)OR', -C(S)OR', -C(O)SR', -C(S)SR', -C(O)NR"(OR'), -C(S)NR"(OR'), -C(O)NR"(SR'), -C(S)NR"(SR'), -CH(CN)₂, -C(O)NR'₂, -C(S)NR'₂, -CH[C(O)R']₂, -CH[C(S)R']₂, -CH[C(O)OR']₂, -CH[C(S)OR']₂, -CH[C(O)SR']₂, -CH[C(S)SR']₂, -CH₂OR', or -CH₂SR'; or a mono- or polycyclic aryl group selected from the group consisting of phenyl,

biphenyl, naphthyl, and cyclopenta-2,4-diene-1-ylidene, or a mono- or poly-heterocyclic group, the mono- or poly-heterocyclic group is a 5- and 6 membered heterocyclic monocyclic group selected from the group consisting of furanyl, imidazolyl, isoimidazolyl, 2-isoimidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl, piperidyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, and butyrolactonyl, and which mono- or polycyclic groups may optionally be substituted one or more times with substituents selected from the group consisting of hydrogen, halogen, trihalogenmethyl, alkyl, cycloalkyl, alkenyl, alkynyl, amino, nitro, cyano, -OR', and -SR';

R' and R", independently of each another, represents hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, or alkoxy.

Claim 18. (Three Times Amended) The method according to claim 1, wherein the compound is (4-chlorophenyl-diphenyl)-carbinol; Ethyl 2-phenyl-2-(1-piperidyl)-phenylacetate; or 1,1,1-triphenylacetone; or a pharmaceutically acceptable salt or an oxide or a hydrate thereof.

26. (Amended) The method according to any one of claims 1, 4,
E10 6, 8, 10, 12, 14, 16, or 18, wherein said butyrolactonyl is α -
butyrolactonyl.

Attached hereto is a version with markings to show changes
made to this application by the Reply.